Sundaram Senthil Vel 4
4 · Axovant Gene Therapies Ltd. · Filed Jul 1, 2019
Insider Transaction Report
Form 4
Sundaram Senthil Vel
Director
Transactions
- Award
Stock Option ( Right to Buy)
2019-06-27+18,750→ 18,750 totalExercise: $6.19Exp: 2029-06-26→ Common Shares (18,750 underlying)
Footnotes (1)
- [F1]The common shares underlying this option vest over a period of three years, with one-third of the common shares vesting on each of the first, second and third anniversaries of June 27, 2019, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.